The FDA has posted briefing documents for Thursday’s meeting of the Endocrinologic and Metabolic Drugs Advisory Committee to reconsider the new drug application for lorcaserin (Lorqess, Arena). The reviewers do not appear to have substantially altered their view of lorcaserin.

Following rejections earlier this year of two previous anti-obesity drugs, the FDA’s Endocrinologic and Metabolic Drugs advisory committee has recommended approval for Contrave, the combination of sustained-release formulations of naltrexone and buproprion from Orexigen Therapeutics. The committee voted 13-7 in favor of the drug, saying that the benefits of Contrave outweighed its risks. The committee…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.